• NIAID Selects Metabolon for COVID-19 Study americanpharmaceuticalreview
    December 09, 2020
    Metabolon will participate in the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, Immunophenotyping Assessment in a COVID-19 Cohort, or IMPACC, study (grant no: 5U19AI118602-04).
PharmaSources Customer Service